March 25th 2025
Under the agreement, AstraZeneca will use Alteogen’s proprietary hyaluronidase platform technology to develop and commercialize subcutaneous formulations of multiple oncology assets in its portfolio.
February 17th 2025
Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.
Establishing Blend Uniformity Acceptance Criteria for Oral Solid-Dosage Forms
February 2nd 2017This article introduces the concepts of pooled variance and the central limit theorem, which are intended for establishing acceptance criteria for blend uniformity data of granular powder blends when a significant degree of sampling bias is involved.